Fast-acting subperception therapy in spinal cord stimulation (FAST-SCS) uses low-frequency, subthreshold stimulation to engage the dorsal column-mediated surround inhibition mechanism and thereby relieve pain. Our study was performed to better characterize the multidimensional long-term clinical outcomes of FAST-SCS therapy in patients with chronic low back and/or leg pain. Our prospective, multicenter, single-arm, open-label trial, conducted at 12 pain management centers across the USA, included male and female patients with chronic low back pain with/without leg pain refractory to conservative therapy. All eligible patients received an SCS implant. Outcomes evaluated included pain relief, disability, mobility, health-related quality of life, sleep quality, depression, pain catastrophizing, and global impression of change. Fifty-six patients received a permanent SCS implant and 55 were activated with FAST-SCS therapy. At 12 months, 89 https://www.clinicaltrials.gov/study/NCT04618471 .
Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine malignancy that most commonly presents in elderly patients as a rapidly growing lesion on sun-exposed skin. Because of its nonspecific clinical appearance, it can mimic a variety of benign and malignant soft tissue conditions, making diagnosis challenging. We report a rare presentation of MCC in a 74-year-old male who presented to the orthopedic clinic with a progressively enlarging soft tissue mass on the dorsoradial aspect of his right forearm. The patient reported a six-week history of swelling and constant radial-sided forearm pain that failed to improve with oral antibiotics and corticosteroids. Physical exam demonstrated a firm, deep subcutaneous mass with overlying mild warmth and flushing. Magnetic resonance imaging revealed a heterogeneous, enhancing soft tissue lesion concerning for soft tissue sarcoma, but final pathology confirmed MCC. This case highlights the diagnostic challenges of MCC and the importance of early recognition and tissue diagnosis in rapidly enlarging masses.
Background: Evidence is mixed and conflicting regarding emergent ankle injuries by sex and age in basketball. Purpose: To determine during the time frame of 2014-2023 (1) the prevalence and patterns of basketball-related ankle injuries admitted to emergency departments (EDs) and (2) whether prevalence and mechanisms of emergent ankle-related basketball injuries differ by age and sex. Study Design: Descriptive epidemiology study. Methods: Patients who sought care in the ED and were part of the National Electronic Injury Surveillance System were categorized by sex and age groups (13-18, 19-24, and 25-35 years). Annual injury national estimate trends were compared over time by age and sex using linear regression analyses. Injury diagnoses, prevalence, mechanisms, settings (practice vs competition), and treatment dispositions were compared by age and sex using chi-square tests. Odds ratios (ORs) were determined using logistic regression. Results: There were 20,303 patients included in this analysis (15.3% female). Female players sought ED care more frequently than male players for ankle sprains/strains (OR, 1.33; 95% CI, 1.19-1.47) and less often for fractures (OR, 0.57; 95% CI, 0.48-0.67) and dislocations (OR, 0.46; 95% CI, 0.21-0.99) than male players (all P < .05). Patients aged 19 to 24 years and 25 to 35 years had 31% and 22% greater odds of seeking care for sprains/strains and lower odds for fractures and dislocations than patients aged 13 to 18 years ( P < .05). Injuries among male players were associated more often with poor landings than female players (10.0% vs 6.8%); female players had more injuries involving falls (10.8% vs 8.5%), being pushed, and collisions than males (all P < .05). Compared with patients aged 13 to 18 years and 19 to 24 years, those aged 25 to 35 years had fewer ankle injuries involving poor landings and rolling of ankles ( P < .05). The 13- to 18-year-old age group had the greatest involvement in falls and collisions. In total, 98.4% of all cases were treated and released, and 0.4% were hospitalized. Conclusion: Our study demonstrated that sex- and age-related differences exist among diagnoses and injury mechanisms that involved ED visits. Targeted prevention strategies could include neuromuscular and balance programs for youth, ankle stability and proprioception programs for female players, and dorsiflexion mobility and landing biomechanics programs for male players.
Background Spinal cord stimulation (SCS) is an established treatment for chronic pain, but long-term results are limited. The objective of this manuscript was to evaluate the 24-month durability of outcomes for patients with nonsurgical refractory chronic low back pain (NS-CLBP) treated with implanted burst SCS, including common diagnoses of NS-CLBP, and predictors of SCS success. Methods The DISTINCT study was a prospective, multicenter, randomized, controlled trial that investigated the use of SCS for NS-CLBP compared to conventional medical treatment alone. Efficacy and safety data were collected after the optional crossover at 6 months. Univariable and multivariable regression analyses were performed for predictor analyses at 24 months. Dependent variables were pain intensity (NRS), back pain-related disability (ODI), and pain catastrophizing (PCS). Independent variables were selected baseline characteristics, including the PainDetect questionnaire to assess pain as neuropathic (vs. mechanical/nociceptive). Results NRS responder rates (≥50% reduction) at 24 months for SCS and crossover patients were of 77% and 79%, respectively. Secondary outcomes indicated significant sustained improvements in ODI, PCS, and reduced healthcare utilization. Six serious adverse events were reported and resolved without sequelae. Improvements on the NRS, ODI, and PCS for common subetiologies mirrored those of the overall NS-CLBP group. After adjusting for covariates, higher baseline PCS scores and leg pain were predictors of super-responders, or patients who responded to all 3 scales. Patients with predominantly neuropathic pain reported more robust 24-month ODI and PCS outcomes than patients with mechanical/nociceptive pain. Patients reported similar NRS improvements regardless of pain type. Conclusions Implanted passive recharge burst SCS provides a significant and sustained therapeutic effect 2 years after implantation in patients with NS-CLBP. Even patients with the highest symptom burden report success at 24 months. Although neuropathic pain increases the magnitude of burst SCS success in NS-CLBP, particularly regarding disability and catastrophizing, patients with nociceptive pain also obtain substantial benefit.